Imugene’s VAXINIA MAST trial progressed with first patient dosed

Imugene Limited (ASX: IMU) has reported that the Phase 1 MAST study, evaluating the safety of its novel cancer-killing virus CF33-hNIS (VAXINIA), has commenced. The trial will investigate the efficacy of the virus in patients with metastatic or advanced solid tumours who have undergone at least two previous lines of standard care treatment. The study will consist of low doses of VAXINIA, delivered to patients via intratumoral or intravenous means, and Pembrolizumab, a well-known drug, in combination.

The study will be conducted in approximately 10 trial sites across the United States and Australia, with a total of 100 patients expected to participate. The trial aims to identify VAXINIA's potential benefits when used in combination with Pembrolizumab. Imugene CEO Leslie Chong stated that the trial was progressing at an excellent pace and looked forward to data and results in the future.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com